Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Scenesse (afamelanotide) is indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Afamelanotide (Scenesse) demonstrated a moderate positive effect in reducing skin photosensitivity in patients with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), as observed in controlled trials.
• Inorganic sunscreen also showed a moderate positive effect in controlled trials, whereas organic sunscreen, beta-carotene, cysteine, N-acetylcysteine, vitamin C, and warfarin showed no effect in similar trials.
• Treatments such as foundation cream, dihydroxyacetone/lawsone cream, and others suggested potential effectiveness in uncontrolled studies, but the actual effects remain uncertain due to the lack of control and possible bias.
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.